SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

201646 citationsJournal Articlegold Open Access

Authors

Christoph Rochlitz · University Hospital of Basel

Martin Bigler · Swiss Group For Clinical Cancer Research

Roger von Moos · Kantonsspital Graubünden

Jürg Bernhard · University Hospital of Bern

Klazien Matter‐Walstra

Andreas Wicki · University Hospital of Basel

Khalil Zaman

Sandro Anchisi

Abstract

This trial failed to meet its primary endpoint of a reduced rate of prespecified grade 3-5 AEs with metronomic bevacizumab, cyclophosphamide and capecitabine.

Topics & Keywords

Cancer Treatment and Pharmacology HER2/EGFR in Cancer Research Breast Cancer Treatment Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Cancer

Volume 16, Issue 1, pp. 780-780

DOI: 10.1186/s12885-016-2823-y

Field-Weighted Citation Impact: 3.31